Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors

BACKGROUND: Varlitinib is a highly potent, small-molecule, pan-HER inhibitor targeting HER1, HER2, and HER4. It has demonstrated activity in gastric, biliary tract, and breast cancers. OBJECTIVE: We conducted a phase Ib dose confirmation study to determine safety and early efficacy signals of varlit...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Matilda Xinwei, Wong, Andrea L. A., Ow, Samuel, Sundar, Raghav, Tan, David S. P., Soo, Ross A., Chee, Cheng Ean, Lim, Joline S. J., Yong, Wei Peng, Lim, Siew Eng, Goh, Boon Cher, Wang, Lingzhi, Lee, Soo Chin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995271/
https://www.ncbi.nlm.nih.gov/pubmed/35195837
http://dx.doi.org/10.1007/s11523-022-00867-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995271/
https://www.ncbi.nlm.nih.gov/pubmed/35195837
http://dx.doi.org/10.1007/s11523-022-00867-0

Ejemplares similares